Connection
Jeffrey Goldstein to Cytochrome P-450 Enzyme Inhibitors
This is a "connection" page, showing publications Jeffrey Goldstein has written about Cytochrome P-450 Enzyme Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.052 |
|
|
|
-
Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther. 1999 Aug; 290(2):635-40.
Score: 0.044
-
Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996 May; 277(2):805-16.
Score: 0.009